Evidence map›Paper›PMID 42125798›Full record

ArticlemAbs2026

Impact of process impurities on developability assessments of complex antibody formats: the striking role of leachable copper.

Vincent Wieser, Christian Spick, Matthias Forster, Urs Hanke, Katja Montan, Michael Grote, Benjamin Weiche

Abstract read
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vincent WieserLarge Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.ORCID 0009-0006-7590-2537
Christian SpickLarge Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Matthias ForsterLarge Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Urs HankeLarge Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Katja MontanLarge Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Michael GroteLarge Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Benjamin WeicheLarge Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The assessment of developability and physical stability of antibody therapeutics is a cornerstone of modern biopharmaceutical discovery, increasingly relying on high-throughput automation to screen candidates to identify the most suitable lead candidate. In this study, we report a severe, anomalous fragmentation event observed in therapeutic antibodies during routine automated buffer exchange into phosphate-buffered saline (PBS) at physiological pH. Through a systematic investigation, we demonstrate that this instability is not intrinsic to the proteins, but is driven by the specific physicochemical environment of the purification process. We identify that at pH 7.4, the dominant phosphate species may act as a ligand capable of mobilizing trace catalytic copper from disposable chromatography columns. Our data suggests the leached copper coordinates to the antibody hinge region, driving a highly localized, Fenton-like oxidative cleavage. Comparative analysis reveals that this vulnerability is influenced by molecular architecture. Complex formats, such as 2 + 1 CrossMabs, exhibited significantly higher susceptibility than standard IgGs, suggesting that steric crowding may enhance the accessibility of the metal-binding site. Finally, we present a robust mitigation strategy using an ethylenediaminetetraacetic acid-based column conditioning protocol that effectively eliminates the leachable catalyst. These findings highlight a critical, often-overlooked source of chemical instability in automated workflows and underscore the necessity of controlling process-related impurities, particularly when developing complex antibody modalities.

Indexed as

Antibodies, MonoclonalCopperDrug ContaminationImmunoglobulin GHumansHydrogen-Ion ConcentrationOxidation-ReductionProtein StabilityAntibodies, MonoclonalCopperImmunoglobulin GChemical stabilitycopper-catalyzed oxidationdevelopabilityfragmentationhigh-throughput screeningmonoclonal antibody

Identifiers

PMID42125798
PMCPMC13173997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.